Fulcrum Therapeutics, Inc.FULCNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank52
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Percentile
P52
Within normal range
vs 5Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q4 2025-3.82%
Q3 2025-10.31%
Q2 20252.88%
Q1 2025-5.01%
Q4 202422.67%
Q3 2024-147.87%
Q2 2024275.95%
Q1 2024-6.58%
Q4 2023-2.01%
Q3 2023-0.54%
Q2 20232.32%
Q1 20230.12%
Q4 2022-14.86%
Q3 202228.86%
Q2 2022-31.68%
Q1 2022-10.35%
Q4 2021-13.43%
Q3 2021-5.53%
Q2 2021-15.48%
Q1 20214.18%
Q4 20206.89%
Q3 2020-19.97%
Q2 202015.28%
Q1 2020-13.98%
Q4 20193.03%
Q3 2019-26.03%
Q2 201963.75%
Q1 2019-302.41%
Q4 2018-1.79%
Q3 2018-15.79%
Q2 2018-7.37%
Q1 20180.00%